Provided by Tiger Fintech (Singapore) Pte. Ltd.

Innate Pharma SA

2.04
+0.04502.26%
Volume:18.67K
Turnover:37.36K
Market Cap:170.98M
PE:-4.51
High:2.05
Open:1.99
Low:1.96
Close:2.00
Loading ...

Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth

MT Newswires Live
·
10 Jan

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Business Wire
·
10 Jan

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire
·
20 Dec 2024

3 Promising Penny Stocks With Market Caps Under US$300M

Simply Wall St.
·
12 Dec 2024

Innate Pharma Price Target Maintained With a $11.50/Share by HC Wainwright & Co.

Dow Jones
·
09 Dec 2024

Innate Pharma SA Reveals Promising Lacutamab Trial Results

TIPRANKS
·
09 Dec 2024

Innate Pharma announces new data from TELLOMAK study

TIPRANKS
·
09 Dec 2024

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Business Wire
·
09 Dec 2024

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
06 Dec 2024

Innate Pharma partners with IFLI to study IPH6501, to receive $3M upfront

TIPRANKS
·
06 Dec 2024

Innate Pharma, Institute for Follicular Lymphoma Collaborate to Study IPH6501 in Follicular Lymphoma

MT Newswires Live
·
06 Dec 2024

Innate Pharma SA’s Innovations Spotlighted at ASH 2024

TIPRANKS
·
03 Dec 2024

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Business Wire
·
03 Dec 2024

Innate Pharma Releases Its 2025 Financial Calendar

Business Wire
·
20 Nov 2024

Innate Pharma publishes IPH6501 data in Science Immunology

TIPRANKS
·
19 Nov 2024

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Business Wire
·
19 Nov 2024